Bristol-Myers Squibb (BMY) rated highly by Validea's guru fundamental report for low volatility stocks.

From Nasdaq: 2025-02-22 13:00:00

Validea’s guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows it rates highest using the Multi-Factor Investor model based on the strategy of Pim van Vliet, seeking low volatility stocks with strong momentum and high net payout yields. BMY is a large-cap value stock in the Biotechnology & Drugs industry, with a rating of 87% based on fundamentals and valuation. The stock passes the market cap and standard deviation tests, but receives neutral ratings for twelve minus one momentum and net payout yield. Pim van Vliet’s research into conservative factor investing led to the creation of this strategy.



Read more at Nasdaq: BMY Quantitative Stock Analysis | Nasdaq